Next generation preclinical tumor models – Make your drug discovery process faster and more predictive


abc biopply is offering a unique and comprehensive service package to test and optimize anti-cancer compounds on highly indicative and accurate 3D in vitro tumor models. All services are based on our proprietary and unique 3D CoSeedis™ technology.
3D CoSeedis™ is distinguished by:
  • The formation of highly homogenous, uniform and physiologic micro-tumors in vitro
  • Its applicability to cell lines as well as primary tumor cell extracts
  • The ability to integrate cell-to-cell and organ-to-organ communication in the tumor model (e.g. tumor immune microenvironment)

Based on this unique and proprietary technology platform we developed an extensive range of assays to measure tumor behavior after compound treatment.
These assays show outperforming predictiveness profiting from the ultra-sensitive and reliable in chip design.

3D CoSeedis™ Assays are an integral part of abc biopply’s 3D preclinical study services but can also be in-licensed for on-site use at our customer’s locations. Contact us for details and customized license options.

Are you ready to get your cancer drug development to next level? I am looking forward to talking to you about our services in more details.

   Best regards

   Marco Leu, PhD
   Sales & Operation
   abc biopply ag

   Direct Email / Phone +41 (0)79 834 95 56

Back to overview

Contact us